With completion of the renovation, Microbiologics has expanded its custom virology solutions to include Biosafety Level 3 (BSL-3) antiviral services.
With these new capabilities, Microbiologics has launched a menu of cell-based services for SARS-CoV-2 to assist assay developers, evaluate therapeutic solutions and vaccines, and provide inactivated intact virus to researchers and diagnostic companies.
Microbiologics has also expanded its viral capabilities to include reverse genetics systems to create recombinant viruses, increased in-vitro assay capabilities, including cytopathic effect screening, hemagglutination-inhibition testing, neutralization assays, and yield-reduction assays.
The newly renovated space also allows for increased capacity for viral propagation of high-titer stock materials. Microbiologics has also recently completed its process for ISO 13485 accreditation at the San Diego Facility.
Microbiologics is a global provider of infectious disease biomaterials. Microbiologics has provided clinical, food, water, pharmaceutical and cosmetic laboratories with reliable, ready-to-use microbial reference materials for nearly 50 years.
The company has a distribution network that reaches more than 140 countries worldwide.
Microbiologics acquired San Diego based Virapur in 2017 expanding its research and development support services to therapeutics, vaccines and gene therapy, as well as broaden its viral molecular controls portfolio.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses